Population PK and Exposure-Response Modeling to Support the Design of Trials with DEBIO 0123, a WEE1 Inhibitor, in Cancer Patients

Presented at the PAGE meeting 2024

Vito Dozio 1, Philippe B. Pierrillas 2, Kyriakos P. Papadopoulos 3, Hans Gelderblom 4, Sandrine Micallef 1, Xavier Lavé 1, Camille Riff 1, Hashim Michla 1, Tri Tat 1,
Marie-Claude Roubaudi-Fraschini 1, Noémie Luong 1, Mokhtar Omar 1, Rikke Frederiksen Franzen 1, Mélanie Wirth 1, Caroline Mathon 1, Victor Rodriguez Freixinos
1, Esteban Rodrigo Imedio 1, Anne Bellon 1

1 Debiopharm International SA, Lausanne, Switzerland,
2 Certara, Basel, Switzerland,
3 START San Antonio, TX, USA,
4 Department of Medical Oncology, University, Medical Center, Leiden, The Netherlands